GlassScriptPhysician profile
Rani Anbarasu
NPI 1326252255
$5,005.45
in general payments reported to CMS, 2019-2025
35 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $188 · 2021: $394 · 2022: $745 · 2023: $1,210 · 2024: $1,019 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.39 |
| Education | $158.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,339.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $645.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.69 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $408.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $269.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $145.63 | 2021-2023 | Veozah |
| Abbvie INC. | $144.74 | 2020-2024 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $126.50 | 2021-2025 | |
| Pfizer INC. | $123.45 | 2019-2022 | |
| Amarin Pharma, INC. | $115.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $102.63 | 2019-2022 | |
| Radius Health, INC. | $94.75 | 2019-2025 | Tymlos |
| Sunovion Pharmaceuticals INC. | $93.81 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.29 | 2019-2023 | |
| Lilly USA, LLC | $88.47 | 2021-2023 | Mounjaro, Jardiance, Emgality |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Anbarasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.